Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mural Oncology plc - Ordinary Shares
(NQ:
MURA
)
3.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mural Oncology plc - Ordinary Shares
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
November 20, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
November 13, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Participate in Two Upcoming Investor Conferences
November 11, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 07, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 07, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
September 26, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
September 23, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Present at Two Upcoming Investor Conferences
August 27, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
August 13, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
July 31, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
June 05, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
April 09, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 26, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
January 08, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.